Cyclin dependent kinase (CDK) inhibitors as anticancer drugs

被引：208
|
作者：
Sanchez-Martinez, Concepcion [1 ]
Gelbert, Lawrence M. [2 ]
Jose Lallena, Maria [1 ]
de Dios, Alfonso [3 ]
机构：
[1] Eli Lilly & Co, Discovery Chem Res & Technol, Alcobendas 28108, Madrid, Spain
[2] Indiana Univ, Herman B Wells Ctr Pediat Res, Sect Pediat Hematol Oncol, Indianapolis, IN 46202 USA
[3] Eli Lilly & Co, Discovery Chem Res & Technol, Indianapolis, IN 46285 USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2015年 / 25卷 / 17期
关键词：
CDK inhibitors; Cell cycle; CELL-CYCLE; ANTITUMOR-ACTIVITY; CANCER-THERAPY; IN-VITRO; POTENT; DISCOVERY; COMBINATION; IDENTIFICATION; OPTIMIZATION; PEPTIDES;
D O I：
10.1016/j.bmcl.2015.05.100
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Sustained proliferative capacity is a hallmark of cancer. In mammalian cells proliferation is controlled by the cell cycle, where cyclin-dependent kinases (CDKs) regulate critical checkpoints. CDK4 and CDK6 are considered highly validated anticancer drug targets due to their essential role regulating cell cycle progression at the G1 restriction point. This review provides an overview of recent advances on cyclin dependent kinase inhibitors in general with special emphasis on CDK4 and CDK6 inhibitors and compounds under clinical evaluation. Chemical structures, structure activity relationships, and relevant preclinical properties will be described. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码：3420 / 3435
页数：16
相关论文
共 50 条
  • [1] Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs
    Krystof, Vladimir
    Uldrijan, Stjepan
    CURRENT DRUG TARGETS, 2010, 11 (03) : 291 - 302
  • [2] Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019)
    Sanchez-Martinez, Concepcion
    Lallena, Maria Jose
    Sanfeliciano, Sonia Gutierrez
    de Dios, Alfonso
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (20)
  • [3] Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
    Roskoski, Robert, Jr.
    PHARMACOLOGICAL RESEARCH, 2016, 107 : 249 - 275
  • [4] Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
    Roskoski, Robert, Jr.
    PHARMACOLOGICAL RESEARCH, 2019, 139 : 471 - 488
  • [5] Indenopyrazoles as novel cyclin dependent kinase (CDK) inhibitors
    Nugiel, DA
    Etzkorn, AM
    Vidwans, A
    Benfield, PA
    Boisclair, M
    Burton, CR
    Cox, S
    Czerniak, PM
    Doleniak, D
    Seitz, SP
    JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (09) : 1334 - 1336
  • [6] Cdk pathway: Cyclin-dependent kinases and cyclin-dependent kinase inhibitors
    Diana M. Gitig
    Andrew Koff
    Molecular Biotechnology, 2001, 19 : 179 - 188
  • [7] Cdk pathway: Cyclin-dependent kinases and cyclin-dependent kinase inhibitors
    Gitig, DM
    Koff, A
    MOLECULAR BIOTECHNOLOGY, 2001, 19 (02) : 179 - 188
  • [8] Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics
    Law, Mary E.
    Corsino, Patrick E.
    Narayan, Satya
    Law, Brian K.
    MOLECULAR PHARMACOLOGY, 2015, 88 (05) : 846 - 852
  • [9] Novel cyclin-dependent kinase 4 (Cdk4) inhibitors as potential anticancer agents.
    Joshi, KS
    Rathos, M
    Mahajan, P
    Wagh, V
    Shenoy, S
    Lai, B
    Mascarenhas, M
    Kamble, S
    Kulkarni, S
    Totre, J
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6222S - 6222S
  • [10] Cyclin-dependent kinase inhibitors: novel anticancer agents
    Mani, S
    Wang, CG
    Wu, KM
    Francis, R
    Pestell, R
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (08) : 1849 - 1870
12345